| Item | 2024 | 2025 | Change |
|---|---|---|---|
| Revenues | 3,205.73 | 4,066.89 | 26.9 % |
| Gross Income | 1,206.84 | 1,452.34 | 20.3 % |
| Operating Income | 567.12 | 645.42 | 13.8 % |
| Net Income | 471.20 | 538.27 | 14.2 % |
| Average Shares | 97.68 | 101.57 | 4.0 % |
| Earnings Per Share before unusual items (Riyals) | 4.82 | 4.66 | (3.3 %) |
| EPS (Riyal) | 4.82 | 5.30 | 9.9 % |
The annual profit growth came as revenue for 2025 rose by 26.9% to SAR 4.06 billion, compared to SAR 3.2 billion a year ago, thanks to higher patient visits.
Operating profit also increased by 13.8% (SAR 78 million) in 2025 to SAR 645 million, compared to SAR 567 million in the prior year. Revenues generated from Dallah’s two newly-acquired hospitals jumped to about SAR 572 million from their acquisition on March 23, 2025, through Dec. 31, 2025, making up 66.4% of the full-year hike in Dallah’s 2025 topline.
In addition, the company’s share of results from associates rose on a yearly basis by approximately SAR 9 million in 2025.
This came as the 2025 losses from the Dallah Al-Khobar Hospital declined by SAR 127 million, or 72.2%, compared to 2024.
This growth came despite the company recognizing white land fees in the fourth quarter of 2025 related to the years 2023, 2024, and 2025 at Care Shield Co., amounting to SAR 12 million. It also recorded provisions and adjustments for obsolete inventory and supply penalties at Dallah Pharma Co., totaling SAR 17 million.
| Item | Q4 2024 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 808.76 | 1,110.44 | 37.3 % |
| Gross Income | 292.76 | 398.23 | 36.0 % |
| Operating Income | 115.40 | 154.94 | 34.3 % |
| Net Income | 113.90 | 116.55 | 2.3 % |
| Average Shares | 97.68 | 101.57 | 4.0 % |
| Earnings Per Share before unusual items (Riyal) | 1.17 | 1.43 | 22.9 % |
| EPS (Riyal) | 1.17 | 1.15 | (1.6 %) |
| Item | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 1,061.26 | 1,110.44 | 4.6 % |
| Gross Income | 380.62 | 398.23 | 4.6 % |
| Operating Income | 148.51 | 154.94 | 4.3 % |
| Net Income | 141.90 | 116.55 | (17.9 %) |
| Average Shares | 101.57 | 101.57 | - |
| Earnings Per Share before unusual items (Riyal) | 1.11 | 1.43 | 29.5 % |
| EPS (Riyal) | 1.40 | 1.15 | (17.9 %) |
Dallah Healthcare’s fourth-quarter net profit grew 2.3% to SAR 116.55 million, from SAR 113.9 million in Q4 2024.
Sequentially, however, the three-month bottomline declined 17.9% from SAR 141.9 million in Q3 2025.
Total shareholders’ equity, after minority interest, increased to SAR 4.08 billion at the end of 2025, from SAR 3.46 billion a year ago.
Attached Document:

| Company | Estimated | Actual | Change |
|---|---|---|---|
| DALLAH HEALTH | 131.87 | 116.55 | |
| FAKEEH CARE | 57.20 | 64.21 | |
| AVALON PHARMA | 45.97 | 44.52 | |
| YCC | 30.40 | 24.57 | |
| SABIC | (17434.05) | (20940.00) | |
| SACO | 9.80 | (3.93) | |
| SAUDI ENERGY | (3760.00) | (894.00) | |
| TAIBA | 87.80 | 66.00 | |
| TADAWUL GROUP | 65.87 | 96.19 | |
| AMAK | 103.50 | 70.94 |
| Company | Estimated | Actual | Change |
|---|---|---|---|
| DALLAH HEALTH | 131.87 | 145.55 | |
| FAKEEH CARE | 57.20 | 64.21 | |
| AVALON PHARMA | 45.97 | 44.52 | |
| YCC | 30.40 | 24.57 | |
| SABIC | (17434.05) | (5740.00) | |
| SACO | 9.80 | 12.23 | |
| SAUDI ENERGY | (3760.00) | (894.00) | |
| TAIBA | 87.80 | 66.00 | |
| TADAWUL GROUP | 65.87 | 96.19 | |
| AMAK | 103.50 | 70.94 |
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: